Incidence, diagnosis, management and outcome of acute mesenteric ischaemia: a prospective, multicentre observational study (AMESI Study).

Publication Year: 2024

DOI:
10.1186/s13054-024-04807-4

PMCID:
PMC10807222

PMID:
38263058

Journal Information

Full Title: Crit Care

Abbreviation: Crit Care

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Critical Care

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participatePrimary ethics approval was obtained from the Research Ethics Committee of the University of Tartu, approval: 357/T-8 and amendment 364M-7. Informed consent was obtained from all participants with full data collection. Patients in whom only baseline data and information on hospital survival were collected, were handled based on local ethics requirements at each site. Informed consent was not obtained for abovementioned patients with limited data collection if a general consent at site was available and a waiver of informed consent was approved by the local ethics committee. Consent for publicationNot applicable. Competing interestsARB has received speaker or consultancy fees from Nestlé, VIPUN Medical, Nutricia and Fresenius Kabi, and is holding a grant from Estonian Research Council (PRG1255). AF has received speaker fees from B Braun and Fresenius Kabi. AN has received speaker or consultancy fees from Abbvie and Janssen, research funding from MSD-Avenir, and PhD grants from Fondation de l’Avenir and SNFGE. SA, MBa, MBj, ZB, DC, MD, ZD, VDMC, HF, MH, BH, KK, MK, KL, ML, CIL, DJM, MMu, MMä, SS, MS, JS, PT, ALV, KV, MAY and KT declare no conflicts of interest. All authors completed the ICMJE uniform conflict of interest disclosure form. Competing interests ARB has received speaker or consultancy fees from Nestlé, VIPUN Medical, Nutricia and Fresenius Kabi, and is holding a grant from Estonian Research Council (PRG1255). AF has received speaker fees from B Braun and Fresenius Kabi. AN has received speaker or consultancy fees from Abbvie and Janssen, research funding from MSD-Avenir, and PhD grants from Fondation de l’Avenir and SNFGE. SA, MBa, MBj, ZB, DC, MD, ZD, VDMC, HF, MH, BH, KK, MK, KL, ML, CIL, DJM, MMu, MMä, SS, MS, JS, PT, ALV, KV, MAY and KT declare no conflicts of interest. All authors completed the ICMJE uniform conflict of interest disclosure form."

Evidence found in paper:

"Funding This study was funded by the Estonian Research Council (Grant PRG1255), covering the costs of the electronic Case Report form and data storage, and partially covering costs of data collection at sites. The funder did not have any role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. All authors had full access to all statistical reports and tables and can take responsibility for the integrity of the data and the accuracy of the data analysis."

Evidence found in paper:

"Trial registration : NCT05218863 (registered 19.01.2022)."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025